申请人:Bristol-Myers Squibb Company
公开号:US05162521A1
公开(公告)日:1992-11-10
This invention relates to a novel process for making a cephem of formula II from 2-(3-amino-2-oxo-azetidin-1-yl)-2,3-butadienoate of formula I. In another aspect, this invention is concerned with a process of further converting a compound of formula II into an antibacterial cephem of formula III. ##STR1## In formulae I, II and III, R.sup.1 is hydrogen, a conventional amino protecting group or an acyl group; R.sup.2 is an aromatic heterocyclic or aryl group; R.sup.3 is a conventional carboxy protecting group or --CO.sub.2 R.sup.3 taken together forms a physiologically hydrolyzable ester; and R.sup.4 is a group selected from the group consisting of C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, cyclic C.sub.3-6 alkyl, and aryl; and n is 0 or 2.
本发明涉及一种从式I的2-(3-氨基-2-氧代-氮杂环丁烯-1-基)-2,3-丁二烯酸酯制备式II头孢菌素的新工艺。另一方面,本发明涉及一种将式II化合物进一步转化为式III抗菌头孢菌素的工艺。在式I、II和III中,R1是氢、传统的氨基保护基或酰基;R2是芳香杂环或芳基基团;R3是传统的羧基保护基或--CO2R3,二者结合形成生理可水解的酯;R4是从C1-6烷基、C2-6烯基、C2-6炔基、环状C3-6烷基和芳基组成的一种基团;n为0或2。